◀ Back to MTOR
FKBP8 — MTOR
Pathways - manually collected, often from reviews:
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Pieretti-Vanmarcke et al., Proc Natl Acad Sci U S A 2006 (Ovarian Neoplasms) :
Because MIS releases
FK506 binding protein ( FKBP12 ), which
activates the
mammalian target of rapamycin (mTOR) downstream of Akt, rhMIS and rapamycin combinations were tested
Yoon et al., J Biol Chem 2011 :
This leads to PA antagonizing
FKBP38 inhibition of
mTORC1 kinase activity in vitro and rescuing mTORC1 signaling from FKBP38 in cells
Dunlop et al., Cell Signal 2009 :
We found that
FKBP38 inhibits
mTOR ( L1460P ), while the mTOR ( E2419K ) kinase domain mutant was resistant to FKBP38 inhibition ... Finally, we show that activation of
mTORC1 by both Rheb and RhebL1 is
impaired by
FKBP38
Wang et al., J Biol Chem 2008 :
Furthermore,
FKBP38 did not
inhibit mTORC1 signaling ... Our data also indicate that, in the mammalian cell lines tested here, neither TCTP nor
FKBP38 regulates
mTORC1 signaling
Peng et al., J Biol Chem 2010 :
Overexpression of NS5A and FKBP38 mutants or FKBP38 knockdown revealed this
mTOR activation was
dependent on
NS5A-FKBP38 interaction ... Additionally, NS5A or
FKBP38 mutants
recovered the
mTOR-FKBP38 interaction ; this indicated that the impairment of mTOR-FKBP38 association was dependent on NS5A-FKBP38 binding
Uhlenbrock et al., FEBS Lett 2009 :
Cell biological experiments illustrate that
FKBP38 plays only a very minor, if any, role in
mTORC1 activation